Clinical Trials Browser

Has results × Carcinoma, Non-Small-Cell Lung × brigatinib × Clear all

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT02706626 2023-01-26

Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors

Phase 2 Terminated

32 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

275 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT01449461 2021-08-17

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

Phase 1/2 Completed

137 enrolled 38 charts

LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Large-Cell, Anaplastic

NCT02094573 2021-03-15

A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Phase 2 Completed

222 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung